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Abstract
Background: PC cell-derived growth factor (PCDGF), also called epithelin/granulin precursor (GEP), is an 88-
kDa secreted glycoprotein with the ability to stimulate cell proliferation in an autocrine fashion. In addition, some
studies indicated that PCDGF participated in invasion, metastasis and survival of cancer cells by regulating cell
migration, adhesion and proliferation. Yet the effects of PCDGF on proliferation and invasion of ovarian cancer
cells in vitro and the mechanisms by which PCDGF mediates biological behaviors of ovarian cancer have rarely
been reported. In the present study we investigated whether and how PCDGF/GEP mediated cell proliferation
and invasion in ovarian cancer.
Methods: PCDGF/GEP expression level in three human ovarian cancer cell lines of different invasion potential
were detected by RT-PCR and western blot. Effects of inhibition of PCDGF expression on cell proliferation and
invasion capability were determined by MTT assay and Boyden chamber assay. Expression levels of cyclin D1 and
CDK4 and MMP-2 activity were evaluated in a pilot study.
Results: PCDGF mRNA and protein were expressed at a high level in SW626 and A2780 and at a low level in
SKOV3. PCDGF expression level correlated well with malignant phenotype including proliferation and invasion
in ovarian cancer cell lines. In addition, the proliferation rate and invasion index decreased after inhibition of
PCDGF expression by antisense PCDGF cDNA transfection in SW626 and A2780. Furthermore expression of
CyclinD1 and CDK4 were downregulated and MMP-2 was inactivated after PCDGF inhibition in the pilot study.
Conclusion: PCDGF played an important role in stimulating proliferation and promoting invasion in ovarian
cancer. Inhibition of PCDGF decreased proliferation and invasion capability through downregulation of cyclin D1
and CDK4 and inactivation of MMP-2. PCDGF could serve as a potential therapeutic target in ovarian cancer.
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Background
PC cell-derived growth factor (PCDGF), also called epi-
thelin/granulin precursor (GEP), is an 88-kDa secreted
glycoprotein purified from the conditioned medium of
the highly malignant mouse teratoma-derived cell line PC
for its ability to stimulate proliferation in an autocrine
fashion [1]. In teratoma cells, PCDGF expression was
shown to be essential for tumorigenicity [2]. High levels
of PCDGF expression are found in rapidly proliferating
cells, such as skin cells, deep crypts of gastrointestinal
tract, and immune cells. On the other hand, low levels of
PCDGF expression are found in cells that are not mitoti-
cally active, such as muscle and liver cells [3,4]. Overex-
pression of PCDGF has been linked to the growth and
tumorigenicity of human breast carcinomas and to the
acquisition of estrogen independence by estrogen recep-
tor-positive breast cancer cells [5-7]. Despite these strong
connections with cancer and growth control, PCDGF 's
mode of action is not well understood.
In addition, some studies indicated that PCDGF partici-
pated in invasion, metastasis and survival of cancer cells
by regulating cell migration, adhesion and proliferation
[8-10]. In SW-13 adrenal carcinoma cells, the level of
PCDGF expression was a major determinant of the intrin-
sic activity of the mitogen-activated protein kinase, phos-
phatidylinositol 3'-kinase, and focal adhesion kinase
signaling pathways [9]. PCDGF resulted in exogenously
stimulated cell growth and sustained cell survival of both
ARP-1 and RPMI 8226 cells in a dose- and time-depend-
ent fashion [10].
The role of growth factors in ovarian cancer development
and progression is complex and multifactorial. Growth
factors identified to date, such as transforming growth fac-
tor-β (TGF-β), macrophage colony stimulating factor (m-
CSF), and lysophosphatidic acid (LPA) have been shown
to regulate ovarian cancer cell growth and survival in vitro
and in vivo [11-14]. Monica BJ et al have reported that
PCDGF was overexpressed in invasive epithelial ovarian
cancer and was involved in the stimulation of ovarian can-
cer cell proliferation [15]. Yet the effects of PCDGF on
ovarian cancer in vitro and the mechanisms by which
PCDGF mediates ovarian cancer biological behaviors
have rarely been reported.
As we know, cyclin D1 can stimulate proliferation by driv-
ing cells from the G1 into the S-phase of the mammalian
cell cycle. Previous studies suggest that the expression of
cyclin D1 could be induced by growth factor stimulation,
and cdk4 or cdk6 associated with cyclin D1 exhibits pro-
tein kinase activity [16-18]. Matrix metallo-proteinases, a
family of zinc-dependent metallo-endopeptidases, are
known to be involved in tumor invasion and metastasis
by degradation of the extracellular matrix. MMP-2, one of
these enzymes, is able to degrade type IV collagen, a major
component of the basement membrane [19-21].
Understanding the mechanisms by which PCDGF medi-
ates tumor biological behaviors could be valuable for
designing potential therapeutic schemes and improving
the survival of ovarian cancer patients. In the present
study we investigated PCDGF expression level in ovarian
cancer cells. We also observed the proliferation rate and
invasion index in Sw626 and A2780 cells after transfec-
tion with antisense PCDGF cDNA. The expression of cyc-
lin D1, CDK4 and the activity of MMP2 along with the
change of PCDGF were determined.
Methods
Cell culture
Human ovarian cancer cell lines SW626, Skov-3 were pur-
chased from the American Type Culture Collection (Man-
assas). They were maintained in Leibovitz's L-15 and
McCoy's 5a media, respectively. Human ovarian cancer
cell line A2780 was obtained from China Type Culture
Center (Wuhan University) and cultivated in RPMI-1640
medium. All of them were cultured in a 37°C incubator
supplied with 5% CO2 and 10% fetal bovine serum (Inv-
itrogen).
Quantitative RT-PCR analysis of PCDGF mRNA 
expression
Total RNA of three human ovarian cancer cell lines was
isolated by TRIzolRNA kit (Gibco BRL) according to the
manufacturer's protocol, 5 μg of total RNA were reverse
transcribed into cDNA, then amplified with equal cDNA.
In PCR analysis the specific primer pairs used were for
PCDGF: forward primer, 5'-AATGTGACATGGAGGT-
GAGC-3' and reverse primer, 5'-AGCAGGTCTGGTTAT-
CATGG-3'; for GAPDH as internal standard: forward
primer, 5'-CCTTCACCATCTTCCAGGAG-3', and reverse
primer, 5'-CCTGCTTCACCACCTTCTTG-3'. The reaction
mixtures were subjected to 30 cycles of PCR. Each cycle
consisted of denaturation at 94°C for 30 sec, annealing at
58°C for 60 sec and extension at 72°C for 60 sec. 10 μl of
each PCR product were analyzed by electrophoresis on
1.5% agarose gels containing 0.5% ethidium bromide.
Immunoprecipitation and Western Blot analyses
Since PCDGF is a secreted protein, its expression was
measured in cell lysates and conditioned media collected
in the presence of a protease inhibitor mixture of 200 μM
phenylmethylsulfonyl fluoride (PMSF)/1 μM leupeptin/
0.5 μM aprotinin/1 mM EDTA (all obtained from Sigma).
Cells were lysed in PBS containing 1% Triton X-100 fol-
lowed by sonication and centrifugation. For comparative
studies of PCDGF expression, the samples used for immu-
noprecipitation and Western blot analysis were normal-
ized to equivalent cell numbers (see figure legends),BMC Cancer 2007, 7:22 http://www.biomedcentral.com/1471-2407/7/22
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determined by counting cells from duplicate sets of
dishes. Immunoprecipitation of PCDGF was carried out
by incubating samples for 4 hr with 5 μg of affinity-puri-
fied anti- PCDGF IgG conjugated to agarose beads fol-
lowed by centrifugation at 10,000 × g for 10 min. Immune
complexes were resuspended in Laemmli sample buffer,
boiled for 5 min, and separated by electrophoresis on a
10% polyacrylamide gel in the presence of SDS. Proteins
were electrophoretically transferred to nitrocellulose
membrane (Schleicher &Schuell) and conjugated to
horseradish peroxidase in the presence of 1% BSA. Immu-
noreactivity was visualized by the enhanced chemilumi-
nescence detection system (Amersham). The membranes
were then blocked with 5% nonfat milk overnight at 4°C
and then incubated for 1 hr at room temperature with 10
ng/ml of polyclonal rabbit anti-PCDGF antibody (1:500,
Santa Cruz, CA), followed by incubation with HRP-conju-
gated goat anti-rabbit-IgG. Immunoreactive proteins were
detected by an enhanced chemiluminescence kit (Pierce,
Rockford, IL).
Quantitative analysis of the RT-PCR and Western blotting
was performed with an imaging densitometer.
Proliferation assay
Ovarian cancer cells in logarithmic growing phase were
detached with 0.25% trypsin. Then 5 × 105 cells were
seeded in each well of 24-well plates. After incubation for
72 h, cell monolayers were fixed and stained with 0.5%
crystal violet in 20% methanol. Specially bound dye was
eluted with a 1:1 solution of 0.1 M sodium citrate (PH
4.2): 100% ethanol. Absorbance at 540 nm was deter-
mined using a microplate reader (BTX).
Matrigel invasion assay
Cell invasion was assessed by a Matrigel invasion assay,
using Transwell chambers (Costar) with 5-μm pore poly-
carbonate filters. The filters were coated with 50 μg of
growth factor-reduced Matrigel (VWR Canlab, Montreal,
Quebec, Canada). Cells (5 × 103) in 25 μl of serum-free
DMEM were placed on each filter, and 26.5 μl of NIH3T3
conditioned medium were placed in the lower chamber as
chemo-attractant. 10 h later the filters were washed, fixed,
and stained as described. Cells on the upper surface of the
filters were removed with cotton swabs. Cells that had
invaded to the lower surface of the filter were counted by
microscopy selecting 10 random fields per filter (×400
magnification).
Construction and transfection of antisense PCDGF cDNA 
expression vector
An antisense PCDGF cDNA expression vector was con-
structed by inserting a partial human PCDGF cDNA (-30
bp to 465 bp) into a pcDNA3.1(+) mammalian expres-
sion vector (Invitrogen) in the antisense orientation. The
recombinant plasmid was certified by DNA sequencing. 4
μg of the antisense PCDGF cDNA construct were trans-
fected into SW626 and A2780 cells with Lipofectamine
(GIBCO) respectively. Each transfectant was selected and
maintained in 800 μg/ml G418, stable clones were iso-
lated after 3 wks and identified by quantitative RT-PCR
and Western blot analysis. SW626 and A2780 cells were
transfected with pcDNA3.1 (+) empty vector plasmid
DNA (vector group). Cells receiving only added Lipo-
fectamine (Lipofectamine group), or only added medium
(blank group) were used as controls.
In order to rule out the possibility of the non-specific
effect, we also transfected PCDGF siRNA (h) (Santa Cruz,
CA) into SW626 and A2780 cells according the manufac-
ture instructions. 48 h after transfection RT-PCR and west-
ern blot were used to evaluate the knock down effects.
MTT assay
Transfected SW626 and A2780 cells were detached with
0.25% trypsin during logarithmic growing phase. After
the cell density was adjusted to 105/ml, 100 μl of cell sus-
pension was seeded in 96-well plates, and cultured in cor-
responding medium containing 10% serum for 48 h.
Then 15 μl of thiazolyl blue (10 g/L) was added in each
well and incubated at 37°C for 3 h until formazan was
formed. Then 100 μl DMSO was added into each well as
a solvent. Absorbance was examined at 570 nm using a
microplate reader (BTX).
Western Blot detection of cyclin D1 and CDK4 expression
Total cell lysates were prepared from subconfluent cells
using lysate buffer [50 mM Tris HCl (pH8.0), 150 mM
NaCl, 0.1% SDS, 100 μg/ml PMSF, 10 μg/ml Aroptinin,
1%NP-40, 0.5%Na3VO4]. Sixty micrograms of cell lysate
were separated by SDS/PAGE on a 10% polyacrylamide
gel and transferred to nitrocellulose membrane (Sch-
leicher &Schuell). The membranes were then blocked
with 5% nonfat milk overnight at 4°C and then incubated
for 1 hr at room temperature with monoclonal mouse
anti-cyclin D1 antibody (1:500, Santa Cruz, CA) and pol-
yclonal rabbit anti-CDK4 antibody (1:500, Santa Cruz,
CA) respectively, followed by incubation with HRP-con-
jugated goat anti-mouse-IgG or goat anti-rabbit-IgG.
Immunoreactive proteins were detected by an enhanced
chemiluminescence kit (Pierce, Rockford, IL).
Quantitative RT-PCR and zymography analysis of MMP-2 
mRNA expression and activity
Total RNA from four groups of human ovarian cancer cells
was isolated by TRIzolRNA kit (Gibco, BRL, Gaithersburg,
MD) according to the manufacturer's protocol, 5 μg of
total RNA were reverse transcribed into cDNA, then
amplified with equal cDNA. In PCR analysis the specific
primer pairs used for MMP-2 were: forward primer, 5'--BMC Cancer 2007, 7:22 http://www.biomedcentral.com/1471-2407/7/22
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GTGCTGAAGGACACACTAAAGAAGA--3' and reverse
primer, 5'-TTGCCATCCTTCTCAAAGTTGTAGG-3'; Thirty
cycles were completed at 94°C for 30s, 58°C for 60s and
72°C for 60s during each cycle.
Gelatin zymography was performed to measure the activ-
ity of MMP-2 in SW626 cells. Conditioned medium from
equal numbers of cells grown under serum-free condi-
tions for 24 hr were electrophoresed on 10% denaturing
SDS/PAGE containing 1 mg/ml gelatin at 4°C, then
washed 1 h in 2.5% TritonX-100 and incubated 16 h at
37°C in reaction buffer [50 mmol/L Tris, 10 mmol/L
CaCl2, 200 mmol/L NaCl, 1 μmol/L ZnCl2 (pH = 7.5)].
Gels were stained with coomassie blue and destained.
Gelatin activities were evaluated by luminance and area of
bands against blue background.
Statistical analysis
All experiments were repeated independently three times,
and data were expressed as mean ± SD. Correlation and
One-Way ANOVA were used for statistical analysis. P <
0.05 was considered as the level of significance.
Results
PCDGF mRNA and protein expression
To detect mRNA and protein expression level of PCDGF in
three ovarian cancer cell lines, quantitative RT-PCR and
Western blot assay were used. The absorbency ratio of
objective bands to reference bands was taken as the quan-
tification standard. In RT-PCR experiments, comparative
absorbencies of SW626, A2780 and Skov-3 cells were 3.69
± 0.05, 2.83 ± 0.05 and 0.86 ± 0.02 respectively (Fig. 1A).
One-Way ANOVA analysis exhibited that there are signif-
icant differences among groups (P < 0.05); In Western
blot assay the ratios in the three cell lines were 0.33 ± 0.05,
0.27 ± 0.04, 0.15 ± 0.04 (Fig. 1B). The difference between
SW626 and A2780 was not significant (P > 0.05), while
the differences between either of them and Skov-3 were
significant (P < 0.05). These results indicate that levels of
PCDGF transcription and translation were coincident in
three ovarian cancer cell lines
Cell proliferation and invasion capabilitiy
To investigate the correlation between the expression lev-
els and the malignant phenotype, cell growth assays and
Boyden chamber in vitro invasion assays were used to
evaluate the capability of proliferation and invasion in
these cells. Cell proliferation capability was figured as
absorbency at 570 nm. The OD570 in SW626, A2780 and
Skov-3 cells were 4.05 ± 0.09, 3.85 ± 0.12 and 1.01 ± 0.06
respectively (Fig. 1C). There were no significant differ-
ences between SW626 and A2780 (P > 0.05), but there
were significant differences between them and Skov-3 (P
< 0.05).
The ratio of the number of cells migrating through
matrigel to the number of cells migrating without
matrigel was defined as the invasion index. The invasion
index was highest in SW626 (46.34 ± 2.40%), lower in
A2780 (26.56 ± 1.09%) and lowest in Skov-3 cells (21.77
± 2.18%) (Fig. 1D). One-Way ANOVA analysis demon-
strated that there were significant differences between
SW626 and A2780 or Skov-3(P < 0.05), but there was no
PCDGF expression in three ovarian cancer cell lines and its  correlation with their malignant phenotype Figure 1
PCDGF expression in three ovarian cancer cell lines 
and its correlation with their malignant phenotype. 
A, PCDGF mRNA expression levels in SW626, A2780 and 
SKOV3 cell lines were determined by RT-PCR. The figure 
shows a representative result of three independent experi-
ments. B, PCDGF protein expression levels in SW626, 
A2780 and SKOV3 cell lines were determined by western 
blot. Also the figure shows a representative result of three 
independent experiments. C, cell proliferation capability of 
SW626, A2780 and SKOV3 cells determined by MTT assay. 
Intensity on 540 nm reflects the cell proliferation capability. 
Values represent the mean ± SE from three independent 
experiments. D, cell invasion capability of SW626, A2780 and 
SKOV3 cells detected by transwell chambers. The ratio of 
the number of cells migrating through matrigel to the 
number of cells migrating without matrigel was defined as 
invasion index. Values represent the mean ± SE from three 
independent experiments. E, the correlation analysis of 
PCDGF mRNA expression level and cell proliferation capa-
bility using Bivariate Correlations in SPSS12.0. F, the correla-
tion analysis of PCDGF mRNA expression level and cell 
invasion capability using Bivariate Correlations in SPSS12.0.BMC Cancer 2007, 7:22 http://www.biomedcentral.com/1471-2407/7/22
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significant difference between A2780 and Skov-3 cells (P
> 0.05).
The data indicated that there was a strong correlation
between the levels of PCDGF mRNA expression and the
capability of proliferation and invasion in ovarian cancer
cell (r1 = 0.97, r2 = 0.89) (Fig. 1E), GEP protein also
reflected this correlation (r1 = 0.85, r2 = 0.84) (Fig 1F). Our
results suggested that PCDGF may play multiple inde-
pendent roles in the processes of ovarian cancer occur-
rence and development.
Transfection of antisense PCDGF cDNA expression vector
To provide a good experimental model for further study of
the molecular characteristics of PCDGF, after sequencing,
the antisense PCDGF eukaryotic expression vector was
transfected into highly malignant ovarian cancer cell lines
by lipofectamine. The stable transfectants were selected
with G418. The expression levels of PCDGF mRNA and
protein decreased sharply in antisense PCDGF transfected
cells detected by RT-PCR and western blot. There were sig-
nificant differences between cells transfected with anti-
sense PCDGF construct and empty vector (P < 0.05), The
inhibitory rates were 53% of mRNA and 72% of protein
expression in Sw626 cells (Fig. 2), and 50% and 70% in
A2780 cells (data not shown), respectively. However there
are no significant differences between the expression lev-
els of control groups (P > 0.05).
Similar results were observed in the PCDGF SiRNA trans-
fected ovarian cells. PCDGF protein expression level was
inhibited by 82% in SW626 cells and 76% in A2780 cells
48 h after PCDGF SiRNA transfection (data to be pub-
lished).
Effects of antisense PCDGF on proliferation and invasion
To observe the inhibitory effects of antisense PCDGF on
proliferation and invasion of highly malignant ovarian
cancer cells, MTT assay and Boyden chamber in vitro inva-
sion assay were used to detect the changes of proliferation
and invasion capability in those cells before and after
transfection. The absorbency on 570 nm and the invasion
index decreased almost 2.5 fold in SW626 and A2780
cells transfected with antisense PCDGF construct than
with empty vector, with significant differences (P < 0.01)
(Fig. 3). There were no significant differences between the
3 control groups (P > 0.05). These data suggested that
antisense PCDGF could remarkably inhibit the prolifera-
tion and invasion of highly malignant ovarian cancer
cells.
Also similar results were observed in the PCDGF SiRNA
transfected ovarian cells. The proliferation rates and inva-
sion index decreased in the SW626 cells and A2780 cells
after PCDGF SiRNA transfection (data to be published).
These data demonstrated that knockdown of PCDGF by
transient transfection of SiRNA could also lead to reversal
of malignant phenotype of ovarian cancer cells.
Expression of MMP-2, Cyclin D1 and CDK4
The effects of PCDGF on the expression and activity of
MMP-2 were evaluated by a quantitative RT-PCR method
and zymography assay respectively. Our results indicated
that MMP-2 gene transcription level did not change in
SW626 after transfection of the antisense PCDGF, while
MMP-9 decreased, which suggested that activation of
MMP-2 was inhibited significantly after PCDGF inhibi-
tion (Fig. 4A, 4B). To make a pilot study whether other
factors were involved in, the protein expression levels of
CyclinD1 and CDK4 before and after transfection were
detected by Western blot method. These observations pro-
vide evidence that the protein expression of CyclinD1 and
CDK4 in antisense PCDGF transfected cells was much
lower than other transfection groups (Fig. 4C).
Discussion
Ovarian cancer is the leading cause of death from gyneco-
logic malignancies because of its special characteristics of
histology and anatomy [22]. Defining more sensitive
biomarkers of ovarian cancer may aid in the development
of targeted therapeutics. PCDGF was originally identified
through studies of the role of autocrine growth factors on
the acquisition of tumorigenic properties in teratoma
tumors and purified as a secreted growth factor from the
highly tumorigenic teratoma PC cells. Biochemical char-
acterization showed that it was an 88-kDa glycoprotein
with a 20-kDa carbohydrate moiety, whereas amino acid
sequencing showed that PCDGF corresponded to a family
of 6-kDa double cysteine-rich polypeptides. The 6-kDa
epithelins, originally purified from rat kidney extracts,
were shown to be dual growth modulators for a variety of
epithelial cell lines. Recently it was reported that PCDGF
might play an important role in tumorigenicity, invasion
and survival in various tumors such as human breast can-
cer, adrenal carcinoma, prostatic adenocarcinoma and
multiple myeloma [1-5]. Neutralizing anti- PCDGF anti-
body reversed basal as well as LPA, ET-1 and 8-CPT-
induced ovarian cancer cell growth and induced apopto-
sis, indicating that PCDGF is a growth and survival factor
for ovarian cancer, induced by LPA and ET-1 and cAMP/
EPAC through ERK1/2 [23]. However, studies on expres-
sion of PCDGF in ovarian cancer cells and the potential
molecular basis of its effects on proliferation and invasion
have rarely been reported. Few studies indicated a poten-
tial mechanism by cyclin and matrix metalloproteinase.
In our study we detected mRNA and protein expression of
PCDGF in three ovarian cancer cells by quantitative RT-
PCR and Western blot assays. The results indicated that
PCDGF was strongly expressed in SW626 and A2780 cells,BMC Cancer 2007, 7:22 http://www.biomedcentral.com/1471-2407/7/22
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whereas it was weakly expressed in SKOV3 cells. The
expression levels of PCDGF in three ovarian cancer cells
were coincident with their malignant phenotype. Cell
growth assay and Boyden chamber in vitro invasion assay
were employed to evaluate the capability of proliferation
and invasion. The capability of proliferation and invasion
showed the same trend: SW626 > A2780 > Skov-3. Bivari-
ate correlation analysis indicated that PCDGF mRNA and
protein expression were positively correlated with the
capability of proliferation and invasion in ovarian cancer.
So we hypothesised that PCDGF may play multiple roles
in the process of ovarian cancer occurrence and develop-
ment as an independent factor, and may be a new molec-
ular target for ovarian cancer.
To provide a good experimental model for further study of
molecular characteristics of PCDGF, the eukaryotic
expression vector for PCDGF antisense RNA was con-
structed successfully, transfected into highly malignant
ovarian cancer cell lines by lipofectamine, and then
detected by RT-PCR and Western-blot assay. The expres-
sion levels of PCDGF mRNA and protein decreased
sharply in antisense PCDGF transfected cells as expected,
which suggested that antisense PCDGF might be an effec-
PCDGF expression level after PCDGF antisense vector and  control vectors transfection in SW626 cells Figure 2
PCDGF expression level after PCDGF antisense vec-
tor and control vectors transfection in SW626 cells. 
A, PCDGF mRNA expression levels were detected by RT-
PCR after transfection of antisense PCDGF construct and 
three control groups including empty control, liposome con-
trol and control vector. The figure shows a representative 
result of three independent experiments. B, PCDGF protein 
expression levels were detected by western blot after trans-
fection of antisense PCDGF construct and three control 
groups as above. C, quantitative detection of PCDGF mRNA 
level after PCDGF antisense vector and control vectors 
transfection in SW626 cells compared with GAPDH. Values 
represent the mean ± SE from three independent experi-
ments. D, quantitative detection of PCDGF protein level 
after PCDGF antisense vector and control vectors transfec-
tion in SW626 cells compared with β-actin. Values represent 
the mean ± SE from three independent experiments.
Cell proliferation and invasion capability decreased after anti- sense PCDGF construct transfection in SW626 and A2780  cells Figure 3
Cell proliferation and invasion capability decreased 
after antisense PCDGF construct transfection in 
SW626 and A2780 cells. A, cell proliferation capability 
was determined by MTT assay after transfection of antisense 
PCDGF construct and three control group. Intensity on 540 
nm reflects the cell proliferation capability. Values represent 
the mean ± SE from three independent experiments. B, cell 
invasion capability was detected by transwell chambers. The 
ratio of the number of cells migrating through matrigel to the 
number of cells migrating without matrigel was defined as 
invasion index. Values represent the mean ± SE from three 
independent experiments. Intensity on 570 nm of cells and 
invasion index were looked as criterions judging the capabil-
ity of proliferation and invasion.BMC Cancer 2007, 7:22 http://www.biomedcentral.com/1471-2407/7/22
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tive strategy for specific inhibition of PCDGF transcrip-
tion and translation in ovarian cancer. Then a good cell
model for observing the inhibitory effects of antisense
PCDGF on their malignant phenotype of ovarian cancer
cells was provided. MTT assay and Boyden chamber in
vitro invasion assays were employed to examine the effect
of PCDGF on proliferation and invasion the capability.
Our results demonstrated that ovarian cancer cells trans-
fected with antisense PCDGF grew more slowly and the
invasion capability in vitro decreased sharply, compared
with the vector transfected cells. In order to rule out the
possibility of the non-specific effect, we adopted SiRNA
strategy. The proliferation rates and invasion index were
decreased in the SW626 cells and A2780 cells after PCDGF
SiRNA transfection as expected.
Interestingly when we introduced antisense PCDGF into
less invasive SKov3 cells, cell proliferation rate and inva-
sion index decreased slightly without statistical signifi-
cance (data not shown), which might indicate that
antisense PCDGF worked more efficiently in highly inva-
sive ovarian cancer cells.
Next we investigated the interrelated mechanism of these
effects. Cyclin D1, one of the G1 cyclins, was identified
independently from human and murine tumors as a puta-
tive proto-oncogene associated with chromosomal trans-
location, gene amplification, and proviral insertion.
Constitutive overexpression of cyclin D1 is likely to con-
tribute to the development of malignancy by reducing the
dependency on mitogens and other extracellular signals
that are normally required to promote progression
through the late G1 restriction point [24,25]. In our pilot
study the protein expression level of CyclinD1 and CDK4
in antisense PCDGF transfected cells were shown to be
much lower than empty vector and other control groups.
Our results implied that inhibition of PCDGF decreased
cell proliferation and invasion through downregulation
of cyclin D and CDK 4.
The changes in the expression and activity of MMP-2
involved in the degradation of the extracellular matrix
were evaluated by a quantitative RT-PCR method and
zymography assay. As we know, invasion across the base-
ment membrane is among the earliest steps of epithelial
tumor progression. Matrix metallo-proteinases, a family
of zinc-dependent metallo-endopeptidases, are involved
in the degradation of the extracellular matrix, a central ele-
ment of tumor invasion and metastasis. One of these
enzymes, MMP-2, is able to degrade type IV collagen,
which is a major component of the basement membrane
There was a significant relationship between activated
MMP-2 and invasiveness, metastasis, and disease progres-
sion [26-29]. In zymography assays we found that the acti-
vated band of MMP-2 disappeared in antisense PCDGF
transfected cells, suggesting that the antisense PCDGF vec-
tor could inhibit the activation of MMP-2 significantly. At
the same time it was demonstrated that the antisense
PCDGF did not change MMP-2 gene transcription.
In conclusion, our present study demonstrated that
PCDGF expression level in ovarian cancer cells correlated
well with their potential for proliferation and invasion.
Inhibition of PCDGF by antisense PCDGF vector could
decrease the proliferation and invasion capability mark-
edly, partially reversing their malignant phenotype. Inhi-
bition of PCDGF decreased cell proliferation and invasion
through downregulation of cyclin D and CDK 4 and inac-
tivation of MMP-2. Taken together, PCDGF might be a
new target for antisense gene therapy of ovarian cancer.
Conclusion
Our present study demonstrated that PCDGF expression
level in ovarian cancer cells correlated well with their
capability of proliferation and invasion capability. Inhibi-
tion of PCDGF by antisense PCDGF transfection could
downregulate the expression of cyclin D1, CDK4 and
MMP-2, and markedly reverses malignant phenotype of
ovarian cancer. PCDGF might be a new target for anti-
sense gene therapy of ovarian cancer.
Abbreviations
PCDGF; PCcell-derivedgrowthfactor, TGF-β; transform-
inggrowthfactor-β, m-CSF; macrophagecolonystimulat-
MMP2, cyclin D1 and CDK4 expression level after antisense  PCDGF construct transfection in SW626 cells Figure 4
MMP2, cyclin D1 and CDK4 expression level after 
antisense PCDGF construct transfection in SW626 
cells. A, MMP2 mRNA expression level was unchanged after 
antisense PCDGF construct transfection in SW626 cells 
compared with control group detected by RT-PCR. B, 
MMP2 activation was inhibited after antisense PCDGF con-
struct transfection in SW626 cells detected by zymography 
assay. The 92KD, 72KD and 68KD bands, which represented 
MMP2 activity, were very weak in antisense PCDGF con-
struct transfection group compared with the control group. 
C, cyclin D1 and CDK4 decreased after antisense PCDGF 
construct transfection in SW626 cells, which paralleled with 
the proliferation and invasion capability.BMC Cancer 2007, 7:22 http://www.biomedcentral.com/1471-2407/7/22
Page 8 of 9
(page number not for citation purposes)
ingfactor, LPA; lysophosphatidicacid, PMSF;
phenylmethylsulfonyl fluoride, SiRNA; small interference
RNA
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
YL and LX carried out these studies and manuscript prep-
aration. GL, WW, XT, BW, GC, ZH, MW and SW partici-
pated in the experiments such as cell culture and
preparation of nucleare extracts, flow cytometry analysis,
immunofluorescence Staining and extracellular hydrogen
peroxide production Assay etc. JZ, GX and YL took care
laboratory supplies and maintained laboratory. DM
directed the design and performance of the study. All
authors read and approved the final manuscript.
Acknowledgements
This work was supported by grants from the National Science Foundation 
of China (No. 30025017, 30571950) and the "973" Program of China (No. 
2002CB513100).
References
1. Zhou J, Gao G, Crabb JW, Serrero G: Purification of an autocrine
growth factor homologous with mouse epithelin precursor
from a highly tumorigeniec cell line.  J Biol Chem 1993,
268:10863-10869.
2. Zhang H, Serrero G: Inhibition of tumorigenicity of the ter-
atoma PC cell line by transfection with antisense cDNA for
PC cell-derived growth factor (PCDGF, epithelin/granulin
precursor).  Cell Biology 1998, 95:14202-14207.
3. He Z, Bateman A: Progranulin gene expression regulates epi-
thelial cell growth and promotes tumor growth in vivo.  Can-
cer Research 1999, 59:3222-3229.
4. Daniel R, He Z, Carmichael KP, Halper J, Bateman A: Cellular local-
ization of gene expression for progranulin.  J Histochem Cyto-
chem 2000, 48:999-1009.
5. Lu R, Serrero G: Inhibition of PC cell-derived growth factor
(PCDGF, epithelin/granulin precursor) expression by anti-
sense PCDGF cDNA transfection inhibits tumorigenicity of
the human breast carcinoma cell line MDA-MB-468.  Proc Natl
Acad Sci 2000, 97:3993-3998.
6. Lu R, Serrero G: Mediation of estrogen mitogenic effect in
human breast cancer MCF-7 cells by PC-cell-derived growth
factor (PCDGF/granulin precursor).  Proc Natl Acad Sci 2001,
98:142-147.
7. Tangkeangsirisin W, Hayashi J, Serrero G: PC cell-derived growth
factor mediates tamoxifen resistance and promotes tumor
growth of human breast cancer cells.  Cancer Res 2004,
64:1737-1743.
8. Xu SQ, Dazhi Tang, Scott Chamberlain, Pronk G, Masiarz FR, Kaur S,
Prisco M, Zanocco-Marani T, Baserga R: The granulin/epithelin
precursor abrogates the requirements for the insulin-like
growth factor I receptor for growth in vitro.  J Biol Chem 1998,
273:20078-20083.
9. He Z, Ismail A, Kriazhev L, Sadvakassova G, Bateman A: Progranulin
(PC-cell-derived growth factor/acrogranin) regulates inva-
sion and cell survival.  Cancer Research 2002, 62:5590-5596.
10. Wang W, Hayashi J, Kim WE, Serrero G: PC cell-derived growth
factor (granulin precursor) expression and action in human
multiple myeloma.  Clin Cancer Res 2003, 9:2221-2228.
11. Fang X, Gaudette D, Furui T, Mao M, Estrella V, Eder A, Pustilnik T,
Sasagawa T, Lapushin R, Yu S, Jaffe RB, Wiener JR, Erickson JR, Mills
GB:  Lysophospholipid growth factorsin the initiation, pro-
gression, metastases, and management of ovarian cancer.
Ann N Y Acad Sci 2000, 905:188-208.
12. Berchuck A, Rodriguez G, Olt G, Whitaker R, Boente MP, Arrick BA,
Clarke-Pearson DL, Bast RC: Regulation of growth of normal
ovarian epithelial cells and ovarian cancer cell lines by trans-
forming growth factor-β.  Am J Obstet Gynecol 1992, 166:676-684.
13. Hurteau JA, Allison B, Sutton GP, Moore DH, Look KY, Hurd W,
Bigsby RM: Transforming growth factor-β_ differentially inhib-
its epithelial ovarian carcinoma cells from primary and met-
astatic isolates without up-regulation of p21WAF1.  Cancer
(Phila.) 1999, 85:1810-1815.
14. Kawakami Y, Nagai N, Ohama K, Zeki K, Kuroda E, Yamashita U:
Macrophage-colony stimulating factor inhibits the growth of
human ovarian cancer cells in vitro.  Eur J Cancer 2000,
36:1991-1997.
15. Jones MB, Michener CM, Blanchette JO, Kuznetsov VA, Raffeld M,
Serrero G, Emmert-Buck MR, Petricoin EF, Krizman DB, Liotta LA,
Kohn EC: The granulin-epithelin precursor/PC-cell- derived
growth factor is a growth factor for epithelial ovarian cancer.
Clin Cancer Res 2003, 9:44-51.
16. Blons H, Laccourreye O, Laurent-Puig P: Cellular and neoplastic
otorhinolaryngologic changes, molecular markers and ther-
apeutic potential. Ann Otolaryngol Chir Cervicofac.  Review
French 2003, 120:152-160.
17. Shao JC, Wu JF, Wang DB, Qin R, Zhang H: Relationship between
the expression of human telomerase reverse transcriptase
gene and cell cycle regulators in gastric cancer and its signif-
icance.  World J Gastroenterol 2003, 9:427-431.
18. Umekita Y, Ohi Y, Sagara Y, Yoshida H: Overexpression of
cyclinD1 predicts for poor prognosis in estrogen receptor-
negative breast cancer patients.  Int J Cancer 2002, 98:415-418.
19. Niedbala MJ, Crickard K, Bernacki RJ: In vitro degradation of
extracellular matrix by human ovarian carcinoma cells.  Clin
Exp Metast 1987, 5:181-197.
20. Afzal S, Lalani EN, Foulkes WD, Boyce B, Tickle S, Cardillo MR, Baker
T, Pignatelli M, Stamp GWH: Matrix metalloproteinase-2 and
tissue inhibitor of metalloproteinase-2 expression and syn-
thetic matrix metalloproteinase-2 inhibitor binding in ovar-
ian carcinomas and tumor cell lines.  Lab Invest 1996, 2:406-421.
21. Leroy-Dudal J, Demeilliers C, Gallet O, Pauthe E, Dutoit S, Agniel R,
Gauduchon P, Carreiras F: Transmigration of human ovarian
adenocarcinoma cells through endothelial extracellular
matrix involves alphav integrins and the participation of
MMP2.  Int J Cancer 2005, 114:531-543.
22. Miyamoto S, Mekada E: Biological behavior of ovarian cancer.
Nippon Rinsho 2004:458-462.
23. Kamrava M, Simpkins F, Alejandro E, Michener C, Meltzer E, Kohn
EC: Lysophosphatidic acid and endothelin-induced prolifera-
tion of ovarian cancer cell lines is mitigated by neutralization
of granulin-epithelin precursor (GEP), a prosurvival factor
for ovarian cancer.  Oncogene 2005, 24:7084-7093.
24. Dimova I, Zaharieva B, Raicheva S, Milev I, Dimitrov R, Doganov N,
Aleksandrov M, Todorov T, Toncheva D: Association of CyclinD1
copy number changes with histological type in ovarian
tumors.  Acta Oncol 2004, 43:675-679.
25. Hashiguchi Y, Tsuda H, Inoue T, Nishimura S, Suzuki T, Kawamura N:
Alteration of cell cycle regulators correlates with survival in
epithelial ovarian cancer patients.  Hum Pathol 2004,
35:165-175.
26. Belotti D, Paganoni P, Manenti L, Garofalo A, Marchini S, Taraboletti
G, Giavazzi R: Matrix metalloproteinases (MMP9 and MMP2)
induce the release of vascular endothelial growth factor
(VEGF) by ovarian carcinoma cells: implications for ascites
formation.  Cancer Res 2003, 63:5224-5229.
27. Okamoto T, Niu R, Yamada S: Increased expression of tissue
inhibitor of metalloproteinase-2 in clear cell carcinoma of
the ovary.  Mol Hum Reprod 2003, 9:569-575.
28. Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A, Tarabo-
letti G, Labianca R, Belotti D, Giavazzi R: Expression levels of vas-
cular endothelial growth factor, matrix metalloproteinases 2
and 9 and tissue inhibitor of metalloproteinases 1 and 2 in
the plasma of patients with ovarian carcinoma.  Eur J Cancer
2003, 39:1948-1956.
29. Holle L, Song W, Holle E, Wei Y, Wagner T, Yu X: A matrix met-
alloproteinase 2 cleavable melittin/avidin conjugate specifi-
cally targets tumor cells in vitro and in vivo.  Int J Oncol 2003,
22:93-98.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2007, 7:22 http://www.biomedcentral.com/1471-2407/7/22
Page 9 of 9
(page number not for citation purposes)
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/7/22/prepub